A discussion between Dr. Peter Anglin and Dr. Matthew S. Davids (Fall 2021)

In this final episode, Dr. Anglin and Dr. Davids discuss recent developments and evidence that is likely to frame the future of CLL management. They review emerging data from trials assessing efficacy and safety of various novel agents and combinations in different patient populations. The experts also discuss promising biomarkers that could assist in therapeutic decision-making and address sequencing-related questions, including the role of MRD monitoring in routine practice.

Peter Anglin, MD, FRCPC, MBA Hematologist/Oncologist Physician Lead, Stronach Regional Cancer Centre Newmarket, ON

Matthew S. Davids, MD, MMSc Hematologist/Oncologist Associate Professor of Medicine, Harvard Medical School Director, Clinical Research, Division of Lymphoma, Dana-Farber Cancer Institute

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.